Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group A: Saline Group Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Ofatumumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 15, 2026, 1:07 PM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

NCT00876902
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 2Phase 3 Interventional

Saline Hypertonic in Preschoolers + CT

NCT02950883
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Active Treatment Group 7% Hypertonic Saline, Control Group 0.9% Isotonic Saline
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Aurora, Colorado • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 15, 2026, 1:07 PM EDT
Withdrawn Phase 4 Interventional

Minocycline Administration During Human Liver Transplantation

NCT02712775
View directory record Official record
Conditions
Liver Disease
Interventions
Minocycline (yes/no), Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

NCT07400718
View directory record Official record
Conditions
Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions
AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device
Device
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 15, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

NCT02701582
View directory record Official record
Conditions
Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions
Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor
Drug · Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
15 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

NCT03197870
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
AKB-9778, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

NCT01089062
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 15, 2026, 1:07 PM EDT
Not listed Not applicable Interventional

Histology Study of Biostimulatory Activity of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic)

NCT04957446
View directory record Official record
Conditions
Nasolabial Fold, Facial Wrinkles
Interventions
Sculptra Aesthetic, Placebo
Device · Other
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 15, 2026, 1:07 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients

NCT05900427
View directory record Official record
Conditions
Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine
Drug
Lead sponsor
Johnny K. Lee
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

NCT01127880
View directory record Official record
Conditions
Hemopneumothorax, Pneumothorax
Interventions
Ancef or Clindamycin, Placebo
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2010 · Synced Oct 15, 2026, 1:07 PM EDT
Recruiting Phase 2 Interventional

Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement

NCT07487246
View directory record Official record
Conditions
Pain Management, Abortion, Second Trimester Abortion, Dilation and Evacuation
Interventions
Ketorolac, oral ibuprofen, Placebo, Lidocaine HCl 1%, Saline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

NCT02873286
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
55 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
12
States / cities
Redding, California • San Diego, California • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 3 Interventional

Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis

NCT05160441
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Corticosteroid, PRP, Pain
Interventions
Platelet Rich Plasma Injection, Corticosteroid Injection, Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure
Biological
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 15, 2026, 1:07 PM EDT
Not listed Phase 4 Interventional

IPACK on Early Pain Scores After ACL Reconstruction

NCT05985629
View directory record Official record
Conditions
Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions
IPACK, PLACEBO
Drug
Lead sponsor
Loyola University
Other
Eligibility
16 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Phentermine and B12 on Weight Loss Among Obese Patients

NCT01719185
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Phentermine and B12, Phentermine
Drug
Lead sponsor
Dr. Michael Lang
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 15, 2026, 1:07 PM EDT
Recruiting Phase 3 Interventional

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

NCT06376916
View directory record Official record
Conditions
Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 1:07 PM EDT
Active, not recruiting Phase 2 Interventional

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

NCT04323735
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Culturelle 10 Billion CFU Capsule
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

NCT03415243
View directory record Official record
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 15, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Gel-200 Versus Placebo in Osteoarthritis of the Knee

NCT00449696
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Gel-200, Placebo
Device
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 15, 2026, 1:07 PM EDT